share_log

Lipocine Announced Results From A Phase 2 Trial Of LPCN 2401 Showing Significant Improvement In Body Composition Through Decreased Fat Mass And Increased Lean Mass Or Fat-free Mass In Obese Patients With At Least One Weight-related Comorbidity

Lipocine Announced Results From A Phase 2 Trial Of LPCN 2401 Showing Significant Improvement In Body Composition Through Decreased Fat Mass And Increased Lean Mass Or Fat-free Mass In Obese Patients With At Least One Weight-related Comorbidity

Lipocine公佈了LPCN 2401的2期試驗結果，顯示至少有一種與體重相關的合併症的肥胖患者通過減少脂肪量和增加瘦肉質量或無脂量來顯著改善身體成分
Benzinga ·  04/11 19:04
Lipocine公佈了LPCN 2401的2期試驗結果，顯示至少有一種與體重相關的合併症的肥胖患者通過減少脂肪量和增加瘦肉質量或無脂量來顯著改善身體成分

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論